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ABSTRACT 
Aim: Interleukin-17 (IL-17) appears to promote the host`s defense against mycobacterial 
infections. This study evaluated the association between IL17A gene polymorphism and 
the risk of Bacillus Calmette-Guérin (BCG) osteitis after newborn vaccination and between 
IL17A gene polymorphism and IL-17A concentrations in serum.  
Methods:  IL17A rs2275913 gene polymorphisms and serum IL-17A concentrations were 
studied in 132 adults aged 21-49 years from across Finland, who had BCG osteitis in 
infancy after a newborn BCG vaccination. The subjects were recruited in 2007-2008 and 
their whole blood samples were sent to the National Institute for Health and Welfare, 
Turku, Finland. Their genotypes and minor allele frequencies were compared with 405 
population-based unvaccinated controls aged two to three months from a prospective birth 
cohort study.  
Results: The genotypes and allele frequencies of IL17A rs2275913 differed significantly 
between the former BCG osteitis patients and controls. The genotype was variant in 75.8% 
of cases and 64.0% of controls (p=0.012) and the minor allele frequency was 50.0% in the 
cases and 41.6% of the controls (p=0.009).  Serum IL-17 concentrations did not differ 
significantly between the cases with wild or variant genotypes.  
Conclusion: IL17A rs2275913 gene polymorphism was associated with a risk of BCG 
osteitis after vaccination. 
 
Key notes:  
x This study evaluated the association between IL17A gene polymorphism and the 
risk of Bacillus Calmette-Guérin (BCG) osteitis after newborn vaccination.  
x We studied 132 adults aged 21-49 years from across Finland, who had BCG 
osteitis in infancy, and 405 population-based unvaccinated controls from a 
prospective birth cohort study.  
x Our findings showed that IL17A rs2275913 gene polymorphism was associated with 
a risk of BCG osteitis after newborn vaccination. 
 
INTRODUCTION 
Interleukin-17A (IL-17A) is the founding member of the group of pro-inflammatory 
cytokines produced by T helper 17 (Th17) cells (1). Th17 cells and Th17-derived cytokines 
participate in the defense against different pathogens, including Mycobacterium 
tuberculosis (1).  The effect of Th17 cells and Th17-derived cytokines may be erroneously 
directed towards the host and result in various disorders with chronic inflammation, 
including autoimmune diseases (2).  
A systematic review, that included three studies on the role of IL-17A in the Bacillus 
Calmette-Guerin (BCG) vaccination and six studies on the role of IL-17A in active and 
latent tuberculosis (TB), showed that the BCG vaccination induced high serum levels of IL-
17A and high serum interferon-gamma (IFN-Ȗ) levels (3). Both IL-17A and IFN-Ȗ increased 
during the conversion from active to latent TB (3).  
In a meta-analysis, IL17F rs763780 and IL17A rs3748067 polymorphisms were associated 
with susceptibility to TB, but it was significant that this only occurred in Asian populations 
(4).. However, no significant associations were found between IL17A rs2275913 
polymorphism and the risk of TB (4).  
We have previously published our findings on polymorphisms of the mannose binding 
lectin (MBL) encoding MBL2 gene, the toll-like receptor 2 (TLR2) subfamily encoding 
genes (TLR1, TLR2, and TLR6) and the IL-10 encoding gene (IL10) in the same cohort of 
132 adults. These adults all suffered from BCG osteitis in infancy after newborn BCG 
vaccinations (5-7). Of the genes that encoded pattern recognising proteins, the variant, low 
MB production associated genotypes of the MBL2 gene (5), and the wild TLR1 genotype 
and variant TLR2 and TLR6 genotypes were associated with an increased BCG osteitis 
risk (6). Interleukins form the next step in innate immunity and four single nucleotide 
polymorphisms (SNPs) of the IL10 gene had no association with the risk of BCG osteitis 
(7).  
The aim of this study was to evaluate the association between IL17A polymorphism 
rs2275913 (-197G>A) and the risk of BCG osteitis after newborn vaccination, by 
comparing the prevalence of that SNP in 132 former BCG osteitis patients and 405 
population-based non-vaccinated controls. The genotypes and minor allele frequencies 
(MAF) were compared between the cases and controls. We also studied the connection 
between IL17A rs2275913 polymorphism and IL-17 concentrations in serum.  
MATERIAL AND METHODS 
Study subjects  
In 2007–2008, we contacted 203 former BCG osteitis patients in Finland with a known 
current address to ask them if they would take part in this study and 160 (78.8%) replied. 
They answered a questionnaire that comprised questions on chronic illnesses, long-term 
medication, repeated or chronic infections and mycobacterial infections. Whole blood 
samples from 132 of the patients, who lived all over Finland, were sent to the laboratory of 
the National Institute for Health and Welfare, Turku, Finland (5,8). Deoxyribonucleic acid 
(DNA) was isolated from 200 ȝL of whole blood and both DNA and serum samples were 
frozen at -70°C for further analyses. For the present study, the frozen samples were 
transferred to the laboratory of Medical Microbiology and Immunology at the University of 
Turku, Turku, Finland, where the SNP rs2275913 of the IL17A gene and serum IL-17 
concentrations were determined.  
BCG osteitis in the study subjects was diagnosed by BCG culture and, or, typical histology 
from 1960-1988 when the study subjects were infants (9,10). At that time, the diagnostics 
of BCG osteitis in Finland was centralised at the Public Health Institute in Helsinki. Blood 
samples for IL17A SNPs and IL-17A concentrations in serum were obtained in 2008-2009 
when the subjects were 21 to 49 years old.  The study subjects completed a questionnaire 
and they did not suffer from any acute infections or exacerbations of any chronic disease 
at the time of sampling (12).  
Controls 
The IL17A rs2275913 genotypes were determined in 405 controls recruited from a study 
called Steps to Children's Healthy Development and Wellbeing, which was a prospective 
birth cohort study of 1,827 children (12). The control group comprised Finnish infants aged 
two to three months, who had not yet been vaccinated, apart from the oral rotavirus 
vaccine. They were all healthy, ethnic Finns, who visited the study clinic from 2008-2010 
(13). All the data on the control subjects used in this study, except for their age and 
gender, were anonymised. 
 IL17A rs2275913 genotyping 
All 132 BCG osteitis patients were genotyped for the IL17A rs2275913 gene (-197G>A) by 
the high-resolution melting analysis (HRMA) (Roche Diagnostics Light Cycler 480, Basel, 
Switzerland) at the laboratory of the University of Turku (14). The primers (forward 5’-
TCTGCCCTTCCCATTTTCCTTC-3’ and reverse 5’-GGTTAAAATTTCCGCCCCCAATT-3’) 
were designed with Primer-BLAST design tools (National Center for Biotechnology 
Information, US National Library of Medicine, Maryland, USA). The amplicon size was only 
70bp, which was small enough to maximise the difference between melting peaks in 
variant genotypes and to avoid the other SNPs. Three samples with known genotypes 
were used to determine the proper concentration of magnesium chloride and annealing 
temperature for assay. The reaction volume was 20µl for each run and this consisted of 
3µl genomic DNA (~8,3ng/µl) and 17µl of master mix, including 10µl melting master dye 
and 0.2µM of forward and reverse primers. The master mix provided a final concentration 
of 3 mM of magnesium chloride. HRMA reactions were run at 95°C for 10 min followed by 
45 cycles amplification at 95°C for 10 sec, at 60°C for 10 sec and at 72°C for 15 sec. After 
the polymerase chain reaction process, the final melting cycle conditions were as outlined 
by Roche: heating to 95°C and holding for one minute, cooling to pre-hold temperature at 
40°C and following this with a melting interval to collect fluorescence from 60°C to 95°C,  
at a ramp rate of 0.2°C per second. In each run, known IL17A rs2275913 standards, 
namely wild type, heterozygote and homozygote variants, were used. 
All the 405 controls were genotyped for IL17A rs2275913 (-197G>A) polymorphism. 
Genotyping from extracted DNA was performed by the Sequenom MassARRAY iPlex Gold 
system (Sequenom Inc, California, USA) at the University of Eastern Finland, Kuopio, 
Finland, as previously described (13).  
The functionality of the IL17A rs2275913 (-197G>A) polymorphism has been documented 
in cell cultures obtained from healthy subjects (15). In vitro stimulated T cells from those 
possessing the variant A allele produced significantly more IL-17 than those without the A 
allele. 
Serum IL-17A measurement 
Serum samples were available from 127 of the 132 former BCG osteitis patients at 21-49 
years of age and this meant that their IL-17A concentrations could be measured. The Bio-
Plex Pro Human IL-17A/F immunoassay kit (Bio-Rad, Helsinki, Finland) was used to 
measure serum IL-17A. The measurement run was carried out using the Bio-Plex 200 
System (Bio-Rad, Helsinki, Finland) and IL-17A measurements were performed according 
to manufacturer’s protocol. One sample with known concentration of IL-17A was used as 
an internal control in all runs. The detection limit of IL-17A was 1.22 pg/ml (13).  
Statistical analyses 
The Statistical Package for the Social Sciences Statistics for Windows, version 19 (IBM 
Corp, New York, USA) was used for the statistical analyses. The distributions of the 
genotypes and MAFs between cases and controls were compared using chi-square and 
Fisher`s exact tests, as appropriate. Exploratory data analyses revealed that serum IL-17 
concentrations were non-normally distributed. Therefore, the Mann-Whitney U test was 
used to compare the concentrations as continuous variables and Fisher´s exact test was 
used for categorised variables between the genotypes. The results are given as 
percentages, medians, interquartile (IQ) ranges 25%-75% and minimum to maximum 
ranges.  
 
Ethics 
The study was approved by the Ethics Committee of the Tampere University Hospital 
District and written consent was obtained from the study subjects, including permission to 
perform genetic studies concerning susceptibility to mycobacterial infections. The samples 
studied in the laboratory were coded so that any personal identification data was removed. 
The study protocol for the control children was approved by the Ethics Committee of the 
Hospital District of South-West, Turku, Finland and written consent was obtained from the 
parents to use their children's blood samples.  
 
RESULTS 
The genotypes of IL17A rs2275913 polymorphism were analysed in 132 former BCG 
osteitis patients with slightly more females (n=73, 55.3%) than males. At the time of 
sampling, 21 (15.9%) of the subjects were 21-30 years old, 88 (66.7%) were 31-40 years 
old and 21 (15.9%) were 41-50 years old.  
 
The genotypes of IL17A rs2275913 (-197G>A), as well as the MAFs, differed significantly 
between the 132 former BCG osteitis patients and 405 population controls (Table 1). The 
minor allele A was more common in the cases (50.0%) than the controls (41.6%), as were 
the variant genotypes GA (50.0% versus 44.7%)  and AA (25.8% versus 19.1%) and the 
combined variant genotypes GA and AA (75.8% versus 64.0%).  
 
The median concentration of serum IL-17A in the 127 former BCG osteitis patients was 
27.09 pg/ml (IQ 13.68-62.25, range 0.00-1973.52). The median IL-17A concentration was 
22.68 pg/ml in 71 females and 32.56 pg/ml in 59 males (p=0.257). At the time of sampling, 
the median IL-17A concentration was 35.56 pg/ml in those aged 21-30 years, 28.94 pg/ml 
in those aged 31-40 years and 22.68 pg/ml in those aged 41-50 years (p=0.949).  
 
There were no significant differences in IL-17A concentrations between those with wild 
and variant genotypes of IL17A rs2275913. As seen in Figure 1, the distributions were 
wide and there were three outliers and eight extreme outliers. The result was negative 
when IL-17A concentrations were analysed as continuous variables (Figure 1) and as 
categorised variables with the limits of 25th, 50th, and 75th  percentiles, or as detected 
versus non-detected (data not shown).  
 
DISCUSSION 
Two main results emerged from this controlled study on IL17A rs2275913 (-197G>A) 
polymorphism in BCG osteitis. First, the GA and AA variant genotypes were significantly 
more common in former BCG osteitis patients than in population-based controls and, in 
line with this, the minor allele A frequencies were significantly higher in BCG osteitis cases 
than in controls. Second, the serum concentrations of IL-17A, in the former BCG osteitis 
patients in adulthood, did not differ significantly between those with variant or wild 
genotypes.  
  
The result that the SNP rs2275913 of the IL17A gene differed significantly between the 
former BCG osteitis patients and controls, suggests that IL-17A plays a role in the 
development of BCG osteitis after a BCG vaccination.  No previous data are available on 
the association of IL17A gene polymorphisms with response to BCG vaccinations or with 
vaccination complications like BCG osteitis. Some data have been published on different 
IL17 polymorphisms and tuberculosis, as summarised in a systematic review (4). IL17A 
rs3748067 and IL17F rs763780 polymorphisms were associated with susceptibility to 
tuberculosis in Asian populations, but not in European populations. However, there were 
no significant associations between the IL17A rs2275913 polymorphism we examined in 
the present study and the tuberculosis risk in either Asian or European populations (4).  
IL17A rs2275913 polymorphism has been associated with a decreased tuberculosis risk in 
the Brazilian population (16).   
 
Serum IL-17A concentrations did not differ between those with variant or wild genotypes 
and this result was similar in continuous analyses and in categorised analyses that 
focused on low concentrations. Our observations differed from the findings of a Finnish 
study that measured serum IL-17A in 93 of the 405 controls included in the present study 
at 13 months of age. That study found that IL-17A was detectable in 6% of the variant AA 
homozygotes, in 33% of the variant GA heterozygotes and in 75% of the wild GG 
homozygotes (13).The concentrations were much higher in the adults in the present study: 
the median was 26.3 pg/ml in those with the variant genotype and 28.94 pg/ml in those 
with the wild genotype, compared to <1.25 pg/ml and 2.5 pg/ml in the infant controls, 
respectively (13). The measurements were carried out with the same method in the same 
laboratory, which means that the differences were not technical.  
 A systematic review published in 2012 (3), included three studies carried out in infants and 
children vaccinated with BCG (17-19). Serum IL-17 concentrations increased significantly, 
as did IFN-Ȗ concentrations, when they were measured three to 12 months after the BCG 
vaccination, compared to pre-vaccination concentrations. There are three possible 
explanations for our negative result on the association between IL17A rs2275913 
polymorphism and serum IL-17A concentrations. An increase in the cytokine 
concentrations may need a stimulus, such as an ongoing infection or a recent vaccination, 
which was no longer present in our adult cohort. The rs2275913 polymorphism we 
selected does not influence the production of IL-17A, although this polymorphism has 
been shown to be functional in cell cultures obtained from healthy subjects (15). The third, 
theoretical possibility is that BCG osteitis in early childhood programmed innate immunity 
to respond with high IL-17 production to different stimuli independently from the IL17 
genotype.  In the present study, the concentrations were multiplied many times when they 
were compared to those measured in the 13-month-old healthy non-vaccinated children by 
the same method in the same laboratory (14).    
 
The main strength of the present study was the unique study cohort of more than 130 
patients who presented with firmly diagnosed BCG osteitis after receiving the BCG 
vaccination as newborn infants. Originally, the total number of BCG osteitis patients was 
222, and as previously published, none of them had died of tuberculosis, the BCG 
infection or another severe infection (9,11).The blood samples were taken when the study 
subjects were adults. The fact that samples were not collected during the BCG infection 
cannot influence the distribution of the polymorphisms, but may explain the absence of any 
significant associations between serum IL-17A concentrations and the subjects with wild 
and variant genotypes. The other strength of the study was that it was carefully controlled 
with regard to polymorphisms, by using more than 400 population-based controls. Despite 
this, the material is rather small for genetic studies, and a risk of type-2 statistical errors 
may be present. In addition, only one IL17A polymorphisms was studied, but just this 
rs2275913 is best studied among different IL17A polymorphisms, and there is both in vitro 
and in vivo evidence that it is functional regulating IL-17A production. 
 
CONCLUSION  
We found evidence that the IL17A rs2275913 (-197G>A) gene polymorphism was 
associated with the risk of BCG osteitis after BCG vaccination. The variant genotypes and 
minor alleles were significantly more common in the 132 former BCG osteitis patients 
studied as adults than in 405 population-based controls studied in early infancy. Since 
BCG vaccination is used globally to protect children from tuberculosis, and risk groups are 
still vaccinated in western countries, research is needed to find genetic or immunologic 
markers to identify children at risk of complications after vaccination. 
 
ABBREVIATIONS 
 
BCG, Bacillus Calmette Guérin 
DNA, deoxyribonucleic acid 
HRMA, high-resolution melting analysis 
IFN-Ȗ, interferon gamma 
IL 10, interleukin 10 
IL 17, Interleukin 17 
MAF, minor allele frequency 
TB, tuberculosis 
Th17, T helper 17 
TLR, toll-like receptor 
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Table 1.  Genotypes of IL17A rs2275913 polymorphisms and minor allele A frequencies in 
132 former BCG osteitis patients and 405 population controls. 
 
Genotypes BCG osteitis 
group 
n=132 
  Control group 
n=405 
 P value 
between 
cases and 
controls 
 n %  n %  
       
GG, wild 32 24.2  146 36.0 --- 
GA, variant 66 50.0  181 44.7 0.035# 
AA, variant 34 25.8  78 19.1 0.014# 
Variant all, GA or 
AA 
 
Allele A (minor) 
100 
 
 
132/264 
75.8 
 
 
50.0 
 259 
 
 
337/810 
64.0 
 
 
41.6 
0.012# 
 
 
0.009 
_______________________________________________________________________ 
Distribution of three genotypes between BCG cases and controls: p=0.033 between cases 
and controls 
# Compared to the wild type 
 
 
  
Figure 1. Serum IL-17A concentrations in 127 former BCG osteitis patients in relation to 
wild and variant genotypes of the IL17A rs2275913 polymorphism.  
The box-plot figure expresses medians and quartiles (Q1, Q3), outliers (Q3 + 1.5 x 
interquartile range Q3-Q1) expressed as small circlesO and extreme outliers (Q3 + 2.0 x 
1.5 x interquartile range) expressed as stars*. Two extreme outliers (1973.52 pg/ml in the 
GG group and 1316 pg/ml in the GA group) are situated outside the figure. 
